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OBJECTIVE—Pathogenic mechanisms underlying diabetes-
induced retinal dysfunction are not fully understood. The aim of
the present study was to show the relationship of the renin-
angiotensin system (RAS) with the synaptic vesicle protein
synaptophysin and neuronal activity in the diabetic retina.
RESEARCH DESIGN AND METHODS—C57BL/6 mice with
streptozotocin-induced diabetes were treated with the angioten-
sin II type 1 receptor (AT1R) blocker telimsartan or valsartan,
and retinal function was analyzed by electroretinography. Retinal
production of the RAS components and phosphorylation of ERK
(extracellular-signal regulated kinase) were examined by immu-
noblotting. Retinal mRNA and protein levels of synaptophysin
were measured by quantitative RT-PCR and immunoblot analy-
ses, respectively. In vitro, synaptophysin levels were also evalu-
ated using angiotensin II–stimulated PC12D neuronal cells
cultured with or without the inhibition of ERK signaling or the
ubiquitin-proteasome system (UPS).
RESULTS—Induction of diabetes led to a signiﬁcant increase in
retinal production of angiotensin II and AT1R together with ERK
activation in the downstream of AT1R. AT1R blockade signiﬁ-
cantly reversed diabetes-induced electroretinography changes
and reduction of synaptophysin protein, but not mRNA, levels in
the diabetic retina. In agreement with the AT1R-mediated post-
transcriptional downregulation of synaptophysin in vivo, in vitro
application of angiotensin II to PC12D neuronal cells caused the
UPS–mediated degradation of synaptophysin protein via AT1R,
which proved to be induced by ERK activation.
CONCLUSIONS—These data indicate the ﬁrst molecular evi-
dence of the RAS-induced synaptophysin degradation and neu-
ronal dysfunction in the diabetic retina, suggesting the possibility
of the AT1R blockade as a novel neuroprotective treatment for
diabetic retinopathy. Diabetes 57:2191–2198, 2008
D
iabetic retinopathy is a vision-threatening dis-
ease with neurodegenerative change due to
chronically progressive microangiopathy. The
earliest functional disruption clinically detect-
able is changes in oscillatory potentials (OPs) measured
by electroretinography (ERG) (1,2). The cellular source of
OPs is regarded as retinal neurons with synapse formation
in the inner retina, including bipolar and amacrine cells
(3). At present, there is no established neuroprotective
treatment for diabetic retinopathy, since molecular mech-
anisms underlying diabetes-induced retinal neuronal dam-
age remain unclear.
We have recently demonstrated that angiotensin II type
1 receptor (AT1R) signaling contributes to diabetes-
induced retinal inﬂammation such as leukocyte adhesion
to the retinal vasculature (4). Angiotensin II functions as a
proinﬂammatory factor to induce the activation of nuclear
factor–B pathway in microvascular endothelial cells (4).
Angiotensin II is a ﬁnal product of the renin-angiotensin
system (RAS) produced from angiotensinogen through
enzymatic cascade reactions, and the RAS components
required for the generation of angiotensin II are reported
to exist in the eye (5–7). Indeed, human surgical samples
from eyes with diabetic retinopathy showed a signiﬁcant
increase in angiotensin II levels (8–10). Increasing evi-
dence has suggested the contribution of the RAS to
diabetes-induced retinal vascular complications including
leukocyte adhesion (4), hyperpermeability (11), and im-
paired blood ﬂow (12); however, little is known about the
pathogenesis of angiotensin II–mediated neuronal dys-
function in the diabetic retina. Although AT1R blockade
led to amelioration of hypertension-induced retinal dys-
function that was exacerbated with diabetes (13), no data
have been reported that show the direct effect of AT1R
signaling on diabetes-induced retinal dysfunction together
with underlying molecular mechanisms.
Recently, we revealed the coexpression of AT1R and
the synaptic protein synaptophysin in the inner retinal
neurons (14), consistent with several previous reports
showing synaptic expression of AT1R in the brain
(15–18). Synaptophysin, the major synaptic vesicle pro-
tein, is a marker of synapses reported to be reduced in
the postmortem brains affected by several neurodegen-
erative diseases (19). Considering that OPs in ERG are
originated from inner retinal neurons bearing AT1R, we
hypothesize that angiotensin II directly induces synap-
tophysin dysregulation and visual functional damage
represented by ERG changes. In the present article, we
report the ﬁrst evidence showing that AT1R signaling
contributes to diabetes-induced retinal dysfunction and
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RESEARCH DESIGN AND METHODS
Induction of diabetes. C57BL/6 mice (Clea, Tokyo, Japan) at the age of 6
weeks were used in diabetes induction. All animal experiments were con-
ducted in accordance with the ARVO (Association for Research in Vision and
Ophthalmology) Statement for the Use of Animals in Ophthalmic and Vision
Research. Animals received intraperitoneal injections of streptozotocin
(Sigma, St. Louis, MO) at the dose of 60 mg/kg body weight for 3 days. Blood
glucose concentrations were measured from the tail vein using Medisafe mini
GR-102 (Terumo, Tokyo, Japan). Development of diabetes was deﬁned by
blood glucose 250 mg/dl 7 days after the ﬁrst injection of streptozotocin.
AT1R blockade in vivo. Mice were intraperitoneally injected with the AT1R
blocker (ARB) telmisartan or valsartan (U.S. Pharmacopeia, Rockville, MD) at
the dose of 5 or 10 mg/kg body weight, respectively, or vehicle (0.25% DMSO
in PBS). The ARB treatment started 22 days after the ﬁrst injection of
streptozotocin for 6 consecutive days and continued until the end of the study
(4-week diabetes at evaluation). The doses used in each ARB group were
determined according to our previous study on diabetes-induced retinal
inﬂammation (4). Telmisartan was a kind gift of Boehringer Ingelheim
(Ingelheim, Germany).
ERG analyses. Animals were dark-adapted for 12 h and prepared under dim
red illumination. Mice were anesthetized with pentobarbital sodium at the
dose of 70 mg/kg body weight and placed on a heating pad that maintained
their body temperature at 35–36°C throughout the experiments. The pupils
were dilated with a mixed solution of 0.5% tropicamide and 0.5% phenyleph-
rine (Mydrin-P; Santen, Osaka, Japan). The ground electrode was a subcuta-
neous needle in the tail, and the reference electrode was placed
subcutaneously between the eyes. The active contact lens electrodes (Mayo,
Inazawa, Japan) were placed on the cornea. Recordings were performed with
PowerLab system 2/25 (AD Instruments, New South Wales, Australia). Re-
sponses were differentially ampliﬁed at the gain of 1,000 times using an AC
(alternate current)-coupled bioampliﬁer ML132 (AD Instruments) and ﬁltered
through a bandpass ﬁlter ranging from 0.3 to 500 Hz to yield a- and b-waves.
OPs were simultaneously recorded using a high-pass ﬁlter set to 100 Hz, so
that an overall bandpass ranging from 100 to 500 Hz was achieved. Light
pulses of 800 cd-s/m
2 were delivered via Ganzfeld System SG-2002 (LKC
Technologies; Gaithersburg, MD). The amplitude and implicit time of the a-
and b-waves and OPs were measured and compared among age-matched
nondiabetic controls and 4-week diabetic animals treated with vehicle,
telmisartan, or valsartan.
In vitro assays. The neuronal cell line PC12D cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum and 10% horse serum (Medical &
Biological Laboratories, Nagoya, Japan). Cells were incubated with 50 g/l
of nerve growth factor (Millipore, Billerica, MA) for differentiation to neurons
for 2 days. The neuronal cells were applied with the ARB telmisartan (10
mol/l) or valsartan (25 mol/l), the proteasome inhibitor MG132 or lactacys-
tin (20 mol/l for both; Calbiochem, San Diego, CA), the lysosome inhibitor
E64 (50 mol/l; Sigma), the extracellular signal–regulated kinase (ERK)
kinase inhibitor U0126 (10 mol/l; Cell Signaling Technology, Beverly, MA) or
PD98059 (10 mol/l; Calbiochem), the phosphatidylinositol 3-kinase inhibitor
LY294002 (20 mol/l; Calbiochem) or wortmannin (100 nmol/l; Sigma), the
Janus kinase inhibitor AG490 (1, 10, or 100 mol/l; Calbiochem), or vehicle.
After 5 min, the pretreated cells were subsequently stimulated with 100 nmol/l
angiotensin II for 30 min. Immediately after the exposure to angiotensin II, the
neuronal cells were subjected to quantitative RT-PCR and immunoprecipita-
tion for synaptophysin and to immunoblot analyses for synaptophysin and
phosphorylated forms of ERK1/2 (p44/p42), Akt (protein kinase B), and signal
transducer and activator of transcription (STAT)-3.
AT1R and ERK1/2 knockdown by RNA interference. Transfections were
performed using Lipofectamine 2000 (Invitrogen) and the SureSilencing short
hairpin RNA (shRNA) kit (SuperArray Bioscience, Frederick, MD) according
to the manufacturers’ instructions. Brieﬂy, 4 g Rat Agtr1a (AT1R), Rat Mapk3
(ERK1), and Rat Mapk1 (ERK2) or control shRNA was incubated with 10 lo f
the transfection reagent in 500 l serum-free medium for 20 min to facilitate
complex formation. The resulting mixture was added to PC12D cells cultured
in a six-well plate with 2 ml medium for 48 h before differentiation.
Quantitative RT-PCR analyses for synaptophysin. Animals were killed
with an overdose of anesthesia. The eyes were immediately enucleated and
the retina was carefully isolated. Total RNA was extracted from the retinas or
PC12D cells using an extraction reagent (TRIzol; Invitrogen), and cDNA was
synthesized with SuperScript III reverse transcriptase (Invitrogen). Real-time
PCR was performed using MX3000 (Stratagene, La Jolla, CA) with PCR
primers for synaptophysin designed by TaqMan Gene Expression Assays
(Applied Biosystems, Foster, CA). The mRNA levels were normalized to
-actin as an internal control.
Immunoblot analyses for angiotensin II, AT1R, synaptophysin, and
phosphorylated forms of ERK, Akt, and STAT3. The isolated retinas or
PC12D cells were placed into lysis buffer (10 mmol/l Tris-HCl [pH 7.6], 100
mmol/l NaCl, 1 mmol/l EDTA, 1% Triton X-100, protease inhibitors). Each
sample was separated with SDS-PAGE and electroblotted to polyvinylidene
ﬂuoride (PVDF) membranes (Millipore, Bedford, MA). After nonspeciﬁc
binding was blocked with 4% skim milk, the membranes were incubated at 4°C
overnight with a rabbit polyclonal antibody against angiotensin II, AT1R
(1:200, 1:100, respectively; Santa Cruz Biotechnology, Santa Cruz, CA), or
phosphorylated forms of ERK, Akt, or STAT3 (1:1,000, 1:500, or 1:1,000,
respectively; Cell Signaling Technology) or a mouse monoclonal antibody
against synaptophysin (1:500; Sigma) or -tubulin (1:2,000; Sigma). The
membranes were then incubated with a horseradish peroxidase–conjugated
goat antibody against rabbit or mouse immunoglobulins or with a biotinylated
secondary antibody followed by avidin-biotin horseradish peroxidase com-
plexes (Vectastain Elite ABC Kit; Vector, Burlingame, CA). The signals were
visualized with chemiluminescence (ECL Blotting Analysis System; Amer-
sham, Arlington Heights, IL), measured by ImageJ software (National Insti-
tutes of Health, Bethesda, MD) and normalized to -tubulin.
Ubiquitination assays. PC12D cells were transfected with a hemagglutinin-
ubiquitin plasmid (provided by Keiji Tanaka, the Tokyo Metropolitan Institute
of Medical Science, Tokyo, Japan) as described above at the time of
differentiation. Forty-ﬁve hours after transfection, the cells were incubated for
3 h with 20 mol/l MG132. The transfected cells were then pretreated with
telmisartan, valsartan, or vehicle and followed by stimulation with angiotensin
II as described above. The stimulated cells were placed into the lysis buffer,
and the cell lysate was applied with a rabbit polyclonal antibody against
synaptophysin (1:25; Sigma). After rocking at 4°C for 1 h, the lysate treated
with anti-synaptophysin antibodies were then added with protein G-sepharose
beads (Sigma) and incubated overnight at 4°C. After washes of nonspeciﬁc
binding to beads, the bound protein was solubilized in sample buffer, loaded
on an SDS-PAGE, and processed for immunoblotting with a rat monoclonal
antibody against hemagglutinin (1:500; Roche Applied Science, Mannheim,
Germany) to detect multi-ubiquitinated synaptophysin and with a mouse
monoclonal antibody against synaptophysin (1:500; Sigma) to conﬁrm the
equal amount of synaptophysin protein applied in each lane.
Statistical analysis. All results were expressed as means  SD. The values
were processed for statistical analyses (one-way ANOVA with Tukey’s post
hoc test), and differences were considered statistically signiﬁcant at P  0.05.
RESULTS
Diabetes-induced retinal production of angiotensin
II and AT1R led to ERK activation. Mice with strepto-
zotocin-induced diabetes showed a signiﬁcant (P  0.05)
decrease in body weight and a signiﬁcant (P  0.01)
increase in blood glucose, compared with age-matched
nondiabetic controls (Table 1). Treatment with telmisar-
TABLE 1
Systemic data
Nondiabetes
Diabetes
Vehicle Telmisartan Valsartan
n 17 17 18 18
Body weight (g) 26.0  1.3 24.2  1.3† 24.8  1.1* 24.3  1.2†
Blood glucose (mg/dl) 156  22 544  64† 539  81† 516  96†
*P  0.05, †P  0.01 vs. nondiabetes.
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cantly (P  0.05) change these metabolic parameters
(Table 1). The retinas from 4-week diabetic mice were
subjected to immunoblot analyses to detect the produc-
tion of the RAS components and its downstream ERK
activation (Fig. 1). Retinal levels of angiotensin II and its
receptor AT1R were signiﬁcantly (P  0.01) higher in
4-week diabetic than in nondiabetic animals (Fig. 1A–C).
Consistently, ERK phosphorylation, enhanced in 4-week
diabetic mice (P  0.01), was signiﬁcantly (P  0.01)
attenuated by AT1R blockade with telmisartan or valsar-
tan to the level equivalent with that in nondiabetic mice
(Fig. 1D and E). In contrast, AT1R blockade did not
attenuate the baseline level of retinal pERK in nondiabetic
mice (data not shown).
Diabetes-induced visual dysfunction was suppressed
by AT1R blockade. To determine the effect of the RAS
activation in the diabetic retina (Fig. 1) on visual function,
we performed ERG analyses (Fig. 2). OP changes includ-
ing the reduced amplitude and prolonged implicit time are
known to occur in the early stage of murine and human
diabetic retinopathy (1,2,20,21). There was no remarkable
difference in a- or b-wave among nondiabetes and 4-week
diabetes treated with vehicle, telimsartan, and valsartan
(data not shown). Importantly, AT1R blockade with telm-
isartan or valsartan signiﬁcantly reversed the reduction of
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FIG. 1. Diabetes-induced retinal production of angiotensin II and AT1R
led to ERK activation. Immunoblot analyses showing the production of
the RAS components (A–C) and ERK activation in the diabetic retina
(D and E). Retinal levels of angiotensin II and AT1R were signiﬁcantly
higher in 4-week diabetic than in nondiabetic mice (A–C). ERK phos-
phorylation, elevated in 4-week diabetic mice, was signiﬁcantly atten-
uated by AT1R blockade with telmisartan or valsartan (D and E). n 
4 for all. *P < 0.05.
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FIG. 2. Diabetes-induced visual dysfunction was suppressed by AT1R
blockade. A: Representative wave responses from an individual mouse
in each group to one ﬂash. A and B: ERG analyses showing that AT1R
blockade with telmisartan or valsartan signiﬁcantly reversed the re-
duction of OP3 and total OPs (OPs) amplitude in 4-week diabetic
mice. Similarly, the implicit time of OP2–3, prolonged in 4-week
diabetic mice, was signiﬁcantly recovered by AT1R blockade (A and C).
n  7–9. *P < 0.05, **P < 0.01.
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4-week diabetic mice (Fig. 2A and B). Similarly, the
implicit time of OP2 and OP3, prolonged in 4-week dia-
betic mice, was signiﬁcantly (P  0.05 for both) recovered
by AT1R blockade to the normal level (Fig. 2A and C). In
contrast, AT1R blockade did not alter normal ERG waves
in nondiabetic mice (data not shown).
Posttranscriptional reduction of synaptophysin in
the diabetic retina was reversed by AT1R blockade.
To investigate the molecular mechanisms underlying the
AT1R-mediated impairment of ERG responses (Fig. 2), we
analyzed the regulation of the synaptic vesicle protein
synaptophysin (Fig. 3), which is abundantly expressed in
the inner retinal neurons (14), the cellular source of OPs
(1,3,22,23). Synaptophysin is indispensable for several
presynaptic functions, including the release of neurotrans-
mitters (24). The retinal levels of synaptophysin protein,
reduced by inducing diabetes, were signiﬁcantly (P  0.01)
reversed in 4-week diabetic mice by AT1R blockade with
telmisartan or valsartan (Fig. 3A and B). In contrast,
mRNA levels of synaptophysin were unaltered in 4-week
diabetic mice treated with vehicle, telimsartan, or valsar-
tan, compared with those in age-matched nondiabetic
controls (Fig. 3C). The discrepancy between the protein
and mRNA levels indicated that the AT1R-mediated de-
cline of synaptophysin in the diabetic retina was posttran-
scriptionally regulated. In contrast, AT1R blockade did not
affect the physiologic level of synatophysin mRNA or
protein in the nondiabetic retina (data not shown).
AT1R-mediated posttranscriptional reduction of syn-
aptophysin was regulated by the ubiquitin-protea-
some system in neuronal cells. To elucidate the
molecular mechanisms involving the AT1R-mediated post-
transcriptional decrease in synaptophysin in the diabetic
retina (Fig. 3), we used the in vitro culture system with
PC12D neuronal cells stimulated with angiotensin II (Fig.
4). In agreement with the in vivo data (Fig. 3), in vitro
application with angiotensin II signiﬁcantly (P  0.01)
reduced synaptophysin protein (Fig. 4A and B), but not
mRNA (Fig. 4C), levels in a posttranscriptional manner,
which were signiﬁcantly (P  0.05 for all) reversed by
AT1R blockade with telmisartan, valsartan, or shRNA for
AT1R knockdown (Fig. 4A, B, and D–F). Because synaptic
vesicle proteins including synaptophysin have recently
proven to be physiologically degraded by the UPS for the
maintenance of synaptic plasticity (25–27), we examined
the involvement of the ubiquitin-proteasome system (UPS)
(Fig. 4G–I) with AT1R-mediated posttranscriptional de-
crease in synaptophysin protein (Fig. 4A–F). Multi-ubiquit-
inated synaptophysin as a high–molecular weight smear,
enhanced by stimulation with angiotensin II, was substan-
tially attenuated by AT1R blockade with telmisartan or
valsartan (Fig. 4G). Application with the proteasome in-
hibitor MG132 or lactacystin, but not the lysosome inhib-
itor E64, led to signiﬁcant (P  0.05) suppression of
angiotensin II–induced degradation of synaptophysin (Fig.
4H and I). In contrast, the baseline levels of synaptophysin
in PC12D cells not stimulated with angiotensin II were
unaffected with these inhibitors (data not shown).
AT1R-mediated ERK activation was required for syn-
aptophysin degradation in neuronal cells. Because
ERK was activated in the downstream of AT1R signaling in
the diabetic retina (Fig. 1), we examined the involvement
of ERK activation (Fig. 5) with AT1R-mediated degrada-
tion of synaptophysin in the neuronal cells (Fig. 4). Con-
sistent with AT1R-mediated ERK activation in the diabetic
retina (Fig. 1), angiotensin II administration induced the
phosphorylation of ERK in the neuronal cells, which was
signiﬁcantly (P  0.05) inhibited by AT1R blockade with
telmisartan or valsartan (Fig. 5A and B). Inhibition of ERK
activation with U0126, PD98059, or shRNA for ERK1/2
knockdown led to signiﬁcant (P  0.05 for all) suppression
of angiotensin II–induced degradation of synaptophysin
(Fig. 5C–H). In addition to ERK signaling, phosphatidyl-
inositol 3-kinase/Akt and Janus kinase/STAT pathways are
known to be in the downstream of AT1R. In the neuronal
cells, angiotensin II treatment also increased the phos-
phorylated forms of Akt and STAT3 (data not shown). In
contrast to ERK involvement (Fig. 5C–H), however, the
phosphatidylinositol 3-kinase inhibitor wortmannin or
LY294002 or the Janus kinase inhibitor AG490 did not
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FIG. 3. Posttranscriptional reduction of synaptophysin in the diabetic
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sin in vitro (data not shown).
DISCUSSION
The present study reveals, for the ﬁrst time to our knowl-
edge, several important ﬁndings concerning the relation-
ship of the RAS with diabetes-related neuronal damage in
vivo and in vitro. In the diabetic retina, the RAS compo-
nents angiotensin II and AT1R were upregulated together
with AT1R’s downstream ERK activation (Fig. 1). AT1R
blockade with telmisartan or valsartan signiﬁcantly re-
versed diabetes-induced OP changes measured by ERG (Fig.
2), known functional abnormalities in human diabetic reti-
nopathy. Moreover, AT1R signaling caused a posttranscrip-
tional decrease in the synaptic vesicle protein synaptophysin
in the diabetic retina, which was rescued by the ARB
application to diabetic mice (Fig. 3). The protein, but not
mRNA, reduction of synaptophysin in neuronal cells was
shown to depend on the UPS, which was enhanced via AT1R
signaling (Fig. 4). Angiotensin II–induced neuronal ERK
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FIG. 4. AT1R-mediated posttranscriptional reduction of synaptophysin was regulated by the UPS in neuronal cells. In vitro application with
angiotensin II signiﬁcantly reduced synaptophysin protein (A and B), but not mRNA (C), levels in a posttranscriptional manner, which were
signiﬁcantly reversed by AT1R blockade with telmisartan or valsartan. The data with the pharmacologic AT1R blockade (A–C) were reproduced
via shRNA for AT1R knockdown (D–F). Multi-ubiquitinated synaptophysin as a high–molecular weight smear, enhanced by stimulation with
angiotensin II, was substantially attenuated by AT1R blockade (G). Application with the proteasome inhibitor MG132 or lactacystin, but not the
lysosome inhibitor E64, led to signiﬁcant suppression of angiotensin II–induced degradation of synaptophysin (H and I). n  4–6. *P < 0.05,
**P < 0.01.
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resulted in the degradation of synaptophysin protein in vitro
(Fig. 5). The use of two different ARBs throughout the
experiments conﬁrmed that the suppression of diabetes-
induced retinal dysfunction and synaptophysin degradation
is a class effect for ARBs. Additionally, our in vitro results
were further conﬁrmed via gene-speciﬁc shRNA knockdown
technique for AT1R and ERK.
In the diabetic retina, the production of angiotensin II
and AT1R was upregulated, leading to ERK activation in
the downstream of AT1R signaling (Fig. 1). Since ERK is
known to be one of AT1R’s signaling pathways, the
present data are compatible with clinical (5,7,28,29) and
experimental (4) studies showing increased angiotensin II
generation in the diabetic eye. The cellular source of
angiotensin II was shown to be retinal glial cells by
immunohistochemistry for human postmortem eyes (30).
In the liver and kidney as well (31–33), diabetes-induced
activation of the RAS causes elevated concentration of
tissue angiotensin II. The tissue RAS activation in diabetes
is explained in part by the ﬁndings that in vitro stimulation
with high glucose enhanced the transcriptional activity of
angiotensinogen gene encoding a precursor protein for
angiotensin I and II (34,35).
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FIG. 5. AT1R-mediated ERK activation was required for synaptophysin degradation in neuronal cells. Angiotensin II administration induced the
phosphorylation of ERK in the neuronal cells, which was signiﬁcantly inhibited by AT1R blockade with telmisartan or valsartan (A and B).
Inhibition of ERK activation with U0126 or PD98059 led to signiﬁcant suppression of angiotensin II–induced decline of synaptophysin (C–E). The
data with the pharmacologic ERK inhibition (C–E) were reproduced via shRNA for ERK1/2 knockdown (F–H). n  4–6. *P < 0.05, **P < 0.01.
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2196 DIABETES, VOL. 57, AUGUST 2008Our ERG analyses demonstrated the reduced amplitude
and prolonged implicit time of OPs in diabetic mice, in
accordance with clinical and experimental data on atten-
uated OP changes in early diabetes (1,2,29). Importantly,
AT1R blockade signiﬁcantly improved these functional
parameters in the diabetic retina to the normal levels
observed in nondiabetic controls (Fig. 2). Reasonably, the
present ERG ﬁndings, in concert with our recent data on
AT1R expression in the inner retinal neurons (14), the
cellular origins of OPs, suggest that the functional recov-
ery of the diabetic inner retina was attributable in part to
the direct effect of AT1R blockade on the inner retinal
neurons.
Several previous studies on neuronal damage in the
diabetic retina showed the cellular changes including the
apoptosis of ganglion and amacrine cells and the activa-
tion of glial cells (36–38). In contrast, the present study
revealed, with the molecular changes in the diabetic
retina, a signiﬁcant decrease in synaptophysin (Fig. 3), the
synaptic vesicle protein capable of maintaining the func-
tion of retinal neurons. Furthermore, AT1R signaling was
shown to play a crucial role in the reduction of synapto-
physin protein (Fig. 3). Pharmacologic studies using tetro-
dotoxin and glycine suggested the cellular origins of OPs
as neurons with synapse formation in the inner retina
including bipolar and amacrine cells (3,22,23), both of
which develop a retinal neuronal network contributing to
visual function. Synatophysin, a well-known marker for
the presynapse, was shown to decrease with the progres-
sion of Parkinson’s disease and Alzheimer’s disease (19).
In the retina as well, pathogenic conditions such as retinal
detachment and inﬂammation caused reduction of synap-
tophysin (14,39). Mice deﬁcient in synaptophysin exhib-
ited a signiﬁcant decrease in the number of synaptic
vesicles (24). The neuron maintains its viability and activ-
ity by interacting with other neurons via synapses; how-
ever, synaptophysin knockouts were for the most part
functionally compensated possibly because of biological
redundancy (24). Although it is reasonable to think about
the possibility of cooperative involvement of several other
synaptic proteins, the diabetes-induced reduction of syn-
aptopysin (Fig. 3) was attributable, at least in part, to the
functional disturbance of neuronal activity in the diabetic
retina. The currently observed suppression of synaptophy-
sin decrease by AT1R blockade (Fig. 3) is likely to rescue
the activity of the AT1R-bearing inner retinal neurons,
leading to the improvement of OP changes (Fig. 2).
The present in vitro data (Figs. 4 and 5) further eluci-
dated the detailed molecular mechanisms underlying the
AT1R-mediated posttranscriptional decrease in synapto-
physin observed in vivo (Fig. 3). Angiotensin II directly
exerted its bioactivity to the neuronal cells via AT1R,
leading to a posttranscriptional decrease in synatophysin
(Fig. 4A–F), which mimicked the in vivo data (Fig. 3).
Interestingly, angiotensin II/AT1R signaling proved to
cause the activation of the UPS, leading to synaptophysin
degradation in neuronal cells (Fig. 4G–I). Although the
UPS was recently shown to play a role in the degradation
of several synaptic proteins (25–27), the present data are
the ﬁrst to reveal the RAS-mediated UPS activation for
synaptic protein degradation in neurons. Out of several
signaling molecules in the downstream of AT1R, the
phosphorylation of ERK, but not Akt or STAT3, was
required for synaptophysin degradation (Fig. 5), suggest-
ing that the UPS-dependent synaptophysin degradation is
mediated by ERK activation. This is supported by several
recent studies showing that the activation of the ERK
pathway promoted the UPS-mediated degradation of the
cell cycle protein Cdc25 (40,41) and the cell survival factor
Bim (42). In the Drosophila eye, ERK signaling was shown
to be required for the physiologic activity of Sina (seven in
absentia), a key molecule for normal photoreceptor devel-
opment (43). Interestingly, the mammalian homologues of
Drosophila Sina, Siahs (seven in absentia homologues),
proved to be synaptophysin-binding proteins functioning
as E3 ubiquitin ligases to regulate the UPS-mediated
degradation of synaptophysin (26). Reasonably, baseline
ERK phosphorylation in the normal retina (Fig. 1) is likely
to play a physiologic role in the UPS-mediated degradation
of synaptophysin for the maintenance of synaptic plastic-
ity (25–27). In the diabetic retina, however, excessive ERK
activation mediated by AT1R (Fig. 1) is thought to induce
the pathologic decline of synaptophysin (Fig. 3), contrib-
uting to neuronal dysfunction demonstrated by ERG (Fig.
2).
In the current study, diabetes-induced retinal dysfunc-
tion and synaptophysin downregulation were successfully
reversed by AT1R signaling blockade in vivo (Figs. 2 and
3). Although future studies are required to determine
whether angiotensin II/AT1R signaling leads to diabetes-
induced neuronal damage systemically or locally in spe-
ciﬁc target organs, AT1R blockade has proven to be
neuroprotective at least in the diabetic eye. Collectively,
our present data show the possibility of AT1R blockade as
a novel therapeutic strategy for neuronal dysfunction in
vision-threatening diabetic retinopathy.
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